0924 GMT - Roche maintaining its 2025 targets, despite the current uncertain political environment from the U.S., reassures investors, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's key growth drivers continue to grow well, whereas new blockbuster eye drug Vabysmo missed consensus' expectations, he says. Shares are flat at 257.90 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 05:24 ET (09:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。